Company Overview
Snapshot
Founded in October 2016 by Chris Mansi, Emily Melton, Manoj Ramachandran, and David Golan, Viz.ai operates with 201–500 employees. The company has raised a total of $289.5 million across 7 funding rounds from 17 investors. In March 2023, Viz.ai secured growth capital financing, with Canadian Imperial Bank of Commerce participating.
Business overview
Viz.ai develops AI-powered intelligent care coordination solutions for multidisciplinary care teams in the Health Tech & Life Sciences sector. The company's core technology leverages artificial intelligence and deep learning to replace conventional care practices with a unified platform, enhancing communication and care coordination. Its products, including Viz LVO and Viz CTP, are FDA-cleared and designed to detect conditions like large vessel occlusion (LVO) strokes and analyze CT perfusion images. Viz.ai serves healthcare providers, particularly doctors and clinics, in the neurology, radiology, and critical care markets, with a focus on early detection and diagnostics through medical decision support and mobile applications.
Strategic signal
In August 2023, Viz.ai received de novo clearance from the FDA for its software designed to detect hypertrophic cardiomyopathy. This clearance signifies regulatory validation for a new AI-driven diagnostic tool, expanding the company's product portfolio beyond stroke detection and indicating a strategic move into broader cardiovascular health. This development positions Viz.ai for market expansion and reinforces its leadership in applying AI to critical medical diagnostics.
Log in to access full profile ›Company Intelligence Q&A
- What was a key regulatory achievement for Viz.ai in 2023?
- In August 2023, Viz.ai received de novo clearance from the FDA for its software to detect hypertrophic cardiomyopathy, expanding its diagnostic capabilities.
- When did Viz.ai secure its most recent growth capital financing?
- In March 2023, Viz.ai received growth capital financing, with Canadian Imperial Bank of Commerce participating.
- What significant funding round did Viz.ai complete in March 2022?
- In March 2022, Viz.ai completed a D Round of funding, with Tiger Global Management.
- What new AI-powered modules did Viz.ai launch in November 2021?
- In November 2021, Viz.ai launched two new AI-powered modules for pulmonary embolism and aortic disease, expanding its diagnostic offerings.
- What was a notable partnership for Viz.ai in May 2021?
- In May 2021, Medtronic partnered with Viz.ai to bring its AI platform for stroke to the EMEA region, aiming to enhance stroke care.